ReviewVisceral medicine2019
Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications.
Review in Visceral medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 77 citations in OpenAlex.
- Serum Gremlin 1 Remains Elevated Following Successful Direct-Acting Antiviral Therapy for Chronic Hepatitis C.Viruses · 2026Article
- Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study.Medicine · 2025Observational
- Article
- Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.Vaccine · 2025Article
- Considerations for equitable distribution of digital healthcare for people who use drugs.BMC health services research · 2025Observational
- Article
- HCV Treatment Outcomes in PWID: Impact of Addiction History on SVR12.Microorganisms · 2024Article
- Epitope-focused immunogens targeting the hepatitis C virus glycoproteins induce broadly neutralizing antibodies.Science advances · 2024Article
- ReLink strategy in diagnosed-but-untreated hepatitis C-positive patients in Germany: report from a single center.Zeitschrift fur Gastroenterologie · 2024Article
- Role of viral hepatitis in pregnancy and its triggering mechanism.Journal of translational internal medicine · 2024Article
- Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals.Archives of endocrinology and metabolism · 2024Article
- Weight Gain and Increased Body Mass Index in Patients with Hepatitis C after Eradication Using Direct-Acting Antiviral Therapy in Taiwan.Diagnostics (Basel, Switzerland) · 2024Article
- Liver in infections: a single-cell and spatial transcriptomics perspective.Journal of biomedical science · 2023Review
- Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients.Infectious diseases and therapy · 2023Article
- Chronic HCV infection promotes cytotoxicity in antigen-specific CD8Frontiers in virology (Lausanne, Switzerland) · 2023Article
- HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV.Biomedicines · 2022Article
- Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection.Lipids in health and disease · 2022Article
- Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study.Journal of pharmaceutical policy and practice · 2021Review
- Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C-Results from the German Hepatitis C-Registry (DHC-R).Biomedicines · 2021Article
- Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes.PLoS pathogens · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic hepatitis C virus (HCV) infection can lead to liver cirrhosis and its complications. Viral eradication is essential to prevent disease progression and reduces liver-related mortality and morbidity. Since the availability of direct-acting antivirals (DAA), HCV treatment has changed significantly. Current treatment strategies for different groups of patients as well as potential risks and caveats will be discussed in this review. SUMMARY: Interferon-free (IFN-free) treatment not only shortens treatment duration, but also achieves high rates of viral clearance and is overall well tolerated. Genotype-restricted but also pangenotypic combinations are available. Usually two DAA of different drug classes are combined. For the majority of the patients, treatment duration ranges from 8 to 12 weeks. Liver and kidney function as well as prior treatment experience and potential drug-drug interactions influence substance choices and treatment duration. However, modern IFN-free treatment is not only safer, but also overall far more simplified and effective. Global HCV eradication might be an ambitious but not completely unrealistic goal to pursue. KEY MESSAGES: IFN-free antiviral treatment is safe and well tolerated. Patients can be treated almost independently of liver function or concomitant disease. Viral eradication is associated with reduced morbidity and mortality and better quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.